{"filing":{"accession_number":"0001104659-26-105052","cik":"0001408443","ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"tm2624766d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926105052/tm2624766d1_8k.htm"},"events":[{"id":31571,"run_id":28980,"accession_number":"0001104659-26-105052","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-09-03","form":"8-K","submitted_at":null,"items":[{"id":34499,"accession_number":"0001104659-26-105052","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:05:37.947447+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34499,"accession_number":"0001104659-26-105052","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Milestone Pharmaceuticals announced China's NMPA approval of etripamil nasal spray for PSVT treatment, marking the first regulatory approval outside the United States. This is a material operational/regulatory milestone that triggers a $2.0 million payment and positions the company for up to $98 million in future milestone payments and royalties through its licensing partner Everest Medicines. While this is a significant product approval event, it does not fit neatly into the specific operational categories (workforce reduction, material contract, partnership) but represents a major regulatory and commercial milestone for the company's pipeline expansion.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-03T20:05:37.947447+00:00","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-09-03"}]}